JP2009526761A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009526761A5 JP2009526761A5 JP2008552481A JP2008552481A JP2009526761A5 JP 2009526761 A5 JP2009526761 A5 JP 2009526761A5 JP 2008552481 A JP2008552481 A JP 2008552481A JP 2008552481 A JP2008552481 A JP 2008552481A JP 2009526761 A5 JP2009526761 A5 JP 2009526761A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- aryl
- heteroaryl
- compound
- optionally
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 72
- 125000000217 alkyl group Chemical group 0.000 claims 59
- 125000001072 heteroaryl group Chemical group 0.000 claims 52
- 125000003118 aryl group Chemical group 0.000 claims 46
- 125000000623 heterocyclic group Chemical group 0.000 claims 26
- 229910052801 chlorine Inorganic materials 0.000 claims 22
- 229910052731 fluorine Inorganic materials 0.000 claims 21
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 20
- 229910052794 bromium Inorganic materials 0.000 claims 19
- 229910052740 iodine Inorganic materials 0.000 claims 19
- 229910005965 SO 2 Inorganic materials 0.000 claims 17
- 125000005842 heteroatom Chemical group 0.000 claims 17
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims 16
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims 15
- 229910052799 carbon Inorganic materials 0.000 claims 14
- 125000000753 cycloalkyl group Chemical group 0.000 claims 13
- 125000000304 alkynyl group Chemical group 0.000 claims 11
- 125000003342 alkenyl group Chemical group 0.000 claims 10
- -1 Carbocycle Chemical group 0.000 claims 9
- 239000000203 mixture Substances 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 125000002950 monocyclic group Chemical group 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 125000002619 bicyclic group Chemical group 0.000 claims 6
- 239000003795 chemical substances by application Substances 0.000 claims 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 5
- 125000004429 atom Chemical group 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 229920006395 saturated elastomer Polymers 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 125000003107 substituted aryl group Chemical group 0.000 claims 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 230000001028 anti-proliverative effect Effects 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000002837 carbocyclic group Chemical group 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 208000019423 liver disease Diseases 0.000 claims 2
- 102000027426 receptor tyrosine kinases Human genes 0.000 claims 2
- 108091008598 receptor tyrosine kinases Proteins 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- GBXQPDCOMJJCMJ-UHFFFAOYSA-M trimethyl-[6-(trimethylazaniumyl)hexyl]azanium;bromide Chemical compound [Br-].C[N+](C)(C)CCCCCC[N+](C)(C)C GBXQPDCOMJJCMJ-UHFFFAOYSA-M 0.000 claims 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- FPYJSJDOHRDAMT-KQWNVCNZSA-N 1h-indole-5-sulfonamide, n-(3-chlorophenyl)-3-[[3,5-dimethyl-4-[(4-methyl-1-piperazinyl)carbonyl]-1h-pyrrol-2-yl]methylene]-2,3-dihydro-n-methyl-2-oxo-, (3z)- Chemical compound C=1C=C2NC(=O)\C(=C/C3=C(C(C(=O)N4CCN(C)CC4)=C(C)N3)C)C2=CC=1S(=O)(=O)N(C)C1=CC=CC(Cl)=C1 FPYJSJDOHRDAMT-KQWNVCNZSA-N 0.000 claims 1
- 125000005330 8 membered heterocyclic group Chemical group 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 208000020084 Bone disease Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010019842 Hepatomegaly Diseases 0.000 claims 1
- 241000257303 Hymenoptera Species 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000031481 Pathologic Constriction Diseases 0.000 claims 1
- 108091000080 Phosphotransferase Proteins 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 108090000190 Thrombin Proteins 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 1
- 230000030833 cell death Effects 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 230000001066 destructive effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 208000014951 hematologic disease Diseases 0.000 claims 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 230000003463 hyperproliferative effect Effects 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 208000033065 inborn errors of immunity Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 102000020233 phosphotransferase Human genes 0.000 claims 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 125000006413 ring segment Chemical group 0.000 claims 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims 1
- 230000036262 stenosis Effects 0.000 claims 1
- 208000037804 stenosis Diseases 0.000 claims 1
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 229960004072 thrombin Drugs 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 0 CCN(*)CCC#CC(C)C Chemical compound CCN(*)CCC#CC(C)C 0.000 description 20
- HZDQAXNJUIJVJT-UHFFFAOYSA-N CC#CCN1CCC(CO)CC1 Chemical compound CC#CCN1CCC(CO)CC1 HZDQAXNJUIJVJT-UHFFFAOYSA-N 0.000 description 1
- FHYOKCKJLDIOTI-UHFFFAOYSA-N CCCC#CCN(CCN(C)C1)C1=O Chemical compound CCCC#CCN(CCN(C)C1)C1=O FHYOKCKJLDIOTI-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US76341406P | 2006-01-30 | 2006-01-30 | |
| PCT/US2007/002352 WO2008063202A2 (en) | 2006-01-30 | 2007-01-30 | Heterobicyclic thiophene compounds for the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009526761A JP2009526761A (ja) | 2009-07-23 |
| JP2009526761A5 true JP2009526761A5 (https=) | 2011-03-10 |
Family
ID=39272752
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008552481A Pending JP2009526761A (ja) | 2006-01-30 | 2007-01-30 | ヘテロ二環式チオフェン化合物および使用の方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8003662B2 (https=) |
| EP (1) | EP1989211A2 (https=) |
| JP (1) | JP2009526761A (https=) |
| CN (1) | CN101522687A (https=) |
| AR (1) | AR059246A1 (https=) |
| CA (1) | CA2636242A1 (https=) |
| TW (1) | TW200806675A (https=) |
| WO (1) | WO2008063202A2 (https=) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100406567C (zh) * | 2002-01-22 | 2008-07-30 | 生物材料公司 | 生物可降解聚合物的干燥方法 |
| AU2006229343A1 (en) * | 2005-03-28 | 2006-10-05 | Kirin Pharma Kabushiki Kaisha | Thienopyridine derivative, or quinoline derivative, or quinazoline derivative, having c-Met autophosphorylation inhibiting potency |
| KR101378716B1 (ko) | 2005-05-20 | 2014-04-10 | 메틸진 인코포레이티드 | Ｖｅｇｆ 수용체 및 ｈｇｆ 수용체 신호전달의 억제제 |
| AU2006313456B2 (en) | 2005-05-20 | 2011-06-23 | Methylgene Inc. | Inhibitors of VEGF receptor and HGF receptor signaling |
| WO2007124181A2 (en) * | 2006-04-21 | 2007-11-01 | Amgen Inc. | Thieno-[2,3-d]pyrimidine and thieno-pyridazine compounds and methods of use |
| JP2009539878A (ja) * | 2006-06-08 | 2009-11-19 | アレイ バイオファーマ、インコーポレイテッド | キノリン化合物および使用方法 |
| EP2038272B8 (en) | 2006-06-30 | 2013-10-23 | Sunesis Pharmaceuticals, Inc. | Pyridinonyl pdk1 inhibitors |
| US7776857B2 (en) * | 2007-04-05 | 2010-08-17 | Amgen Inc. | Aurora kinase modulators and method of use |
| ES2593279T3 (es) | 2007-08-29 | 2016-12-07 | Methylgene Inc. | Procesos e intermedios para preparar inhibidores de cinasa heterocíclicos condensados |
| PL2183254T3 (pl) | 2007-08-29 | 2017-10-31 | Methylgene Inc | Inhibitory aktywności białkowej kinazy tyrozynowej |
| JP5693239B2 (ja) | 2008-01-23 | 2015-04-01 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ４−ピリジノン化合物および癌についてのその使用 |
| EP2255830A1 (en) | 2008-03-03 | 2010-12-01 | Takeda Pharmaceutical Company Limited | Concomitant drug |
| NZ588355A (en) * | 2008-03-05 | 2012-03-30 | Methylgene Inc | Inhibitors of protein tyrosine kinase activity |
| KR20100135780A (ko) * | 2008-03-06 | 2010-12-27 | 제넨테크, 인크. | Ｃ-ｍｅｔ 및 ｅｇｆｒ 길항제로의 조합 요법 |
| TW201000099A (en) | 2008-06-20 | 2010-01-01 | Amgen Inc | S1P1 receptor agonists and use thereof |
| ES2599458T3 (es) * | 2008-10-14 | 2017-02-01 | Sunshine Lake Pharma Co., Ltd. | Compuestos y métodos de uso |
| WO2010126914A1 (en) * | 2009-04-27 | 2010-11-04 | Elan Pharmaceuticals, Inc. | Pyridinone antagonists of alpha-4 integrins |
| EP2432776B1 (en) * | 2009-05-21 | 2019-09-11 | Universite Laval | Methyl sulfanyl pyrimidines useful as antiinflammatories, analgesics, and antiepileptics |
| US9340555B2 (en) | 2009-09-03 | 2016-05-17 | Allergan, Inc. | Compounds as tyrosine kinase modulators |
| AU2010289353B2 (en) * | 2009-09-03 | 2016-12-08 | Allergan, Inc. | Compounds as tyrosine kinase modulators |
| US8258158B2 (en) * | 2009-09-11 | 2012-09-04 | Hoffmann-La Roche Inc. | HSL inhibitors useful in the treatment of diabetes |
| CA2800998A1 (en) | 2010-04-29 | 2011-11-10 | Deciphera Pharmaceuticals, Llc | Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities |
| SG185073A1 (en) | 2010-04-29 | 2012-12-28 | Deciphera Pharmaceuticals Llc | Cyclopropyl dicarboxamides and analogs exhibiting anti-cancer and anti-proliferative activites |
| TW201204733A (en) | 2010-06-25 | 2012-02-01 | Kowa Co | Novel condensed pyridine or condensed pyrimidine derivative, and medicinal agent comprising same |
| CA2911040C (en) | 2012-05-02 | 2021-11-16 | Georgetown University | Treating an .alpha.-synucleinopathy with tyrosine kinase inhibitors |
| WO2014038881A2 (ko) * | 2012-09-06 | 2014-03-13 | 씨제이제일제당 (주) | 피리돈 유도체를 포함하는 단백질 키나제 억제제 |
| US9574135B2 (en) * | 2013-08-22 | 2017-02-21 | Nanoco Technologies Ltd. | Gas phase enhancement of emission color quality in solid state LEDs |
| RU2016141385A (ru) | 2014-03-24 | 2018-04-28 | Дженентек, Инк. | Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf |
| WO2015162515A1 (en) | 2014-04-25 | 2015-10-29 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine d1 ligands |
| US20190262323A1 (en) * | 2016-10-31 | 2019-08-29 | Georgetown University | Compositions and methods for treating neurodegenerative disorders |
| PT3621960T (pt) | 2017-05-11 | 2021-09-16 | Bristol Myers Squibb Co | Tienopiridinas e benzotiofenos úteis como inibidores de irak4 |
| CN109206435B (zh) * | 2017-06-29 | 2020-09-08 | 中国医药研究开发中心有限公司 | 噻吩并[3,2-d]嘧啶类化合物及其制备方法和医药用途 |
| WO2019182274A1 (en) * | 2018-03-08 | 2019-09-26 | Wellmarker Bio Co., Ltd. | Thienopyridine derivatives and pharmaceutical composition comprising same |
| CN120040470A (zh) | 2018-11-20 | 2025-05-27 | 乔治敦大学 | 用于治疗神经退行性、肌退行性和溶酶体贮积病症的组合物和方法 |
| AR119069A1 (es) | 2019-06-04 | 2021-11-24 | Exelixis Inc | Compuestos para el tratamiento de trastornos dependientes de quinasas |
| US20220235064A1 (en) * | 2019-08-02 | 2022-07-28 | Wellmarker Bio Co., Ltd. | Oxo-pyridine fusion ring derivative and pharmaceutical composition comprising same |
| EP3819300A4 (en) * | 2019-09-06 | 2021-11-24 | Wellmarker Bio Co., Ltd. | THERAPEUTIC COMPOSITION BASED ON BIOMARKERS |
| JP7434575B2 (ja) * | 2020-01-07 | 2024-02-20 | メッドシャイン ディスカバリー インコーポレイテッド | 重水素化チエノピリジン系化合物 |
| US20240002394A1 (en) * | 2020-11-24 | 2024-01-04 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Deuterium-modified thienopyridone compound |
| CN115745999A (zh) * | 2021-11-19 | 2023-03-07 | 浙江奥洋新材料有限公司 | 一种可提高反应活性的纤维素碱性醚化、酯化反应溶剂叔丁五元二环胍的结构及其合成路线 |
| CN117209474B (zh) * | 2022-06-10 | 2026-03-10 | 康百达（四川）生物医药科技有限公司 | 吡咯烷衍生物、药物组合物及其在医药上的应用 |
| CN115177618A (zh) * | 2022-07-26 | 2022-10-14 | 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） | Flt3抑制剂在制备治疗急性髓系白血病药物中的应用 |
| CN118894838B (zh) * | 2024-07-11 | 2025-09-02 | 深圳技术大学 | 一种酰胺衍生物及其制备方法和应用 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1028964A1 (en) | 1997-11-11 | 2000-08-23 | Pfizer Products Inc. | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents |
| BR0111377A (pt) | 2000-06-06 | 2003-06-03 | Pfizer Prod Inc | Derivados de tiofeno úteis como agentes anticancerìgenos |
| US20020004511A1 (en) | 2000-06-28 | 2002-01-10 | Luzzio Michael Joseph | Thiophene derivatives useful as anticancer agents |
| WO2003000194A2 (en) | 2001-06-21 | 2003-01-03 | Pfizer Inc. | Thienopyridine and thienopyrimidine anticancer agents |
| AU2002313249B2 (en) | 2001-06-22 | 2008-08-21 | Kirin Pharma Kabushiki Kaisha | Quinoline derivative and quinazoline derivate inhibiting self-phosphorylation of hepatocytus proliferator receptor, and medicinal composition containing the same |
| AU2002357193A1 (en) | 2001-12-19 | 2003-07-09 | Smithkline Beecham Corporation | Thienopyrimidine compounds as protein tyrosine kinase inhibitors |
| AU2003206068A1 (en) | 2002-03-01 | 2003-09-16 | Pfizer Inc. | Indolyl-urea derivatives of thienopyridines useful as anti-angiogenic agents |
| UA77303C2 (en) * | 2002-06-14 | 2006-11-15 | Pfizer | Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use |
| WO2004018430A1 (ja) * | 2002-08-23 | 2004-03-04 | Kirin Beer Kabushiki Kaisha | ＴＧＦβ阻害活性を有する化合物およびそれを含んでなる医薬組成物 |
| CL2003002287A1 (es) | 2002-11-25 | 2005-01-14 | Wyeth Corp | COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS |
| MXPA06002256A (es) | 2003-08-29 | 2006-05-17 | Pfizer | Naftaleno carboxamidas y sus derivados utiles como agentes anti-angiogenicos. |
| ES2314444T3 (es) | 2003-08-29 | 2009-03-16 | Pfizer Inc. | Tienopiridina-fenilacetaminasy sus derivados utiles como nuevos agentes antiangiogenicos. |
| EP2210607B1 (en) | 2003-09-26 | 2011-08-17 | Exelixis Inc. | N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer |
| WO2005080377A1 (ja) | 2004-02-20 | 2005-09-01 | Kirin Beer Kabushiki Kaisha | TGFβ阻害活性を有する化合物およびそれを含んでなる医薬組成物 |
| US7459562B2 (en) | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
| TW200538453A (en) | 2004-04-26 | 2005-12-01 | Bristol Myers Squibb Co | Bicyclic heterocycles as kinase inhibitors |
| WO2005121125A1 (en) * | 2004-06-09 | 2005-12-22 | Pfizer Inc. | Ether-linked heteroaryl compounds |
| US7977345B2 (en) | 2004-07-02 | 2011-07-12 | Exelixis, Inc. | c-MET modulators and method of use |
| ES2438017T3 (es) | 2004-07-30 | 2014-01-15 | Methylgene Inc. | Inhibidores de la señalización del receptor del VEGF y del receptor del HGF |
| JP2008521900A (ja) | 2004-11-30 | 2008-06-26 | アムジエン・インコーポレーテツド | キノリン及びキナゾリン類似体並びにがん治療のための医薬としてのその使用 |
| AU2006229343A1 (en) | 2005-03-28 | 2006-10-05 | Kirin Pharma Kabushiki Kaisha | Thienopyridine derivative, or quinoline derivative, or quinazoline derivative, having c-Met autophosphorylation inhibiting potency |
| EP1874759A4 (en) | 2005-04-06 | 2009-07-15 | Exelixis Inc | C-MET MODULATORS MODULATORS AND METHODS OF USE |
| JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
| KR101378716B1 (ko) | 2005-05-20 | 2014-04-10 | 메틸진 인코포레이티드 | Ｖｅｇｆ 수용체 및 ｈｇｆ 수용체 신호전달의 억제제 |
| AU2006313456B2 (en) | 2005-05-20 | 2011-06-23 | Methylgene Inc. | Inhibitors of VEGF receptor and HGF receptor signaling |
| WO2007033196A1 (en) | 2005-09-14 | 2007-03-22 | Bristol-Myers Squibb Company | Met kinase inhibitors |
| CA2651072A1 (en) | 2006-05-01 | 2007-11-08 | Pfizer Products Inc. | Substituted 2-amino-fused heterocyclic compounds |
| WO2008054674A2 (en) | 2006-10-31 | 2008-05-08 | Merck & Co., Inc. | Antidiabetic bicyclic compounds |
-
2007
- 2007-01-30 JP JP2008552481A patent/JP2009526761A/ja active Pending
- 2007-01-30 AR ARP070100391A patent/AR059246A1/es unknown
- 2007-01-30 WO PCT/US2007/002352 patent/WO2008063202A2/en not_active Ceased
- 2007-01-30 CN CNA2007800026090A patent/CN101522687A/zh active Pending
- 2007-01-30 TW TW096103347A patent/TW200806675A/zh unknown
- 2007-01-30 EP EP07870652A patent/EP1989211A2/en not_active Withdrawn
- 2007-01-30 CA CA002636242A patent/CA2636242A1/en not_active Abandoned
- 2007-01-30 US US11/699,830 patent/US8003662B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009526761A5 (https=) | ||
| KR102800132B1 (ko) | Sting 작동 화합물 | |
| JP2010538094A5 (https=) | ||
| JP2013542996A5 (https=) | ||
| JP2014518266A5 (https=) | ||
| JP2019524883A5 (https=) | ||
| JP2006517591A5 (https=) | ||
| AU2018256423A1 (en) | PD-1/PD-L1 inhibitors | |
| JP2013512903A5 (https=) | ||
| JP2007505933A5 (https=) | ||
| JP2018528244A5 (https=) | ||
| SI2953948T1 (en) | Fluorinated integrin antagonists | |
| JP2009504764A5 (https=) | ||
| JP2021502387A5 (https=) | ||
| JP2018522866A5 (https=) | ||
| JP2015514808A5 (https=) | ||
| JP2013544261A5 (https=) | ||
| WO2014128111A1 (de) | 4-substituierte pyrrolo- und pyrazolo-diazepine | |
| JP2017527532A5 (https=) | ||
| JP2013502431A5 (https=) | ||
| JP2007533740A5 (https=) | ||
| JP2015532295A5 (https=) | ||
| JP2012529486A5 (https=) | ||
| JP2010510215A5 (https=) | ||
| JP2014513139A5 (https=) |